Gilder Gagnon Howe & CO LLC Allakos Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$7.87 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $85,643 - $165,386	-16,859 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $205 - $2,685	-24 Reduced 0.14%	16,859 $165,000
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $35,050 - $50,576	-458 Reduced 2.64%	16,883 $1.79 Million
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $6.28 Million - $8.4 Million	-73,616 Reduced 80.93%	17,341 $1.48 Million
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $312,291 - $437,316	-2,846 Reduced 3.03%	90,957 $10.4 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $4 Million - $7.66 Million	50,239 Added 115.32%	93,803 $13.1 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $80,845 - $110,734	-1,217 Reduced 2.72%	43,564 $3.55 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $1.36 Million - $2.5 Million	-30,978 Reduced 40.89%	44,781 $3.22 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $12.4 Million - $26 Million	-277,984 Reduced 78.58%	75,759 $3.37 Million
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $473,674 - $981,188	7,124 Added 2.06%	353,743 $33.7 Million
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $9.74 Million - $28.2 Million	314,284 Added 971.96%	346,619 $27.3 Million
Q2 2019 Aug 13, 2019	SELL	$36.0 - $44.73 $2,952 - $3,667	-82 Reduced 0.25%	32,335 $1.4 Million
Q1 2019 May 17, 2019	SELL	$33.79 - $51.99 $64,437 - $99,144	-1,907 Reduced 5.56%	32,417 $1.31 Million
Q4 2018 Feb 14, 2019	SELL	$31.59 - $62.65 $473 - $939	-15 Reduced 0.04%	34,324 $1.79 Million
Q3 2018 Oct 30, 2018	BUY	$31.25 - $47.64 $1.07 Million - $1.64 Million	34,339 New	34,339 $1.55 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $20.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account